Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

NCT05950516 on ClinicalTrials.gov · last registry update 2023-07-18

478 participants. Its estimated completion date, 24 November 2024, has passed with no update to the record. Primary outcome, as filed: Change in HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Qilu Pharmaceutical Co., Ltd.
Sponsor type: Industry
Enrollment: 478
Started: 2023-07-10
Primary completion: 2024-11-24 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.